SCHEMBL2277993

SCHEMBL2277993

O=C(Nc1cc(-c2cccc(Cl)c2)ccc1C(=O)O)c1ccc(O)cc1

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACLY P53396 4/20 0.65
SERPINE1 P05121 5/20 0.63
SUCNR1 Q9BXA5 1/20 0.59
DHODH Q02127 1/20 0.57
GRIK1 P39086 3/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
NPSR1 Q6W5P4 2/20 0.54
PKM P14618 1/20 0.54
AKR1C4 P17516 1/20 0.53
AKR1C3 P42330 1/20 0.53
AKR1C2 P52895 1/20 0.53
AKR1C1 Q04828 1/20 0.53
KDM4E B2RXH2 1/20 0.52
RXFP1 Q9HBX9 1/20 0.52
KCNK2 O95069 1/20 0.52
KCNK10 P57789 1/20 0.52
HCAR2 Q8TDS4 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2276482 0.91 ACLY (0.74) ACLYSERPINE1SUCNR1DHODHGRIK1
SCHEMBL2272927 0.89 ACLY (0.64) ACLYSERPINE1SUCNR1DHODHGRIK1
SCHEMBL2272605 0.88 DHODH (0.73) ACLYSERPINE1SUCNR1DHODHGRIK1
SCHEMBL2272939 0.87 ACLY (0.71) ACLYSERPINE1SUCNR1DHODHGRIK1
SCHEMBL2269733 0.85 ACLY (0.59) ACLYSERPINE1SUCNR1GRIK1MEN1
SCHEMBL2274563 0.85 ACLY (0.81) ACLYSERPINE1SUCNR1DHODHGRIK1
SCHEMBL2274998 0.84 ACLY (0.80) ACLYSERPINE1SUCNR1DHODHGRIK1
SCHEMBL2274974 0.84 ACLY (0.67) ACLYSERPINE1SUCNR1DHODHGRIK1
SCHEMBL2269365 0.84 MEN1 (0.60) ACLYSERPINE1SUCNR1DHODHGRIK1
SCHEMBL30268074 0.83 SERPINE1 (0.60) ACLYSERPINE1GRIK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 ACLY 653/4885SERPINE1 101/4885SUCNR1 637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.